Apalutamide and Docetaxel Intravenous
Determining the interaction of Apalutamide and Docetaxel Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using DOCEtaxel together with apalutamide. Combining these medications may reduce the blood levels of DOCEtaxel, which may decrease its effectiveness in treating your cancer. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of docetaxel, which is a substrate of the isoenzyme. Rifampin and hyperforin, a component of St. John's wort, have been shown to significantly induce the in vitro metabolism of docetaxel in human hepatocyte cultures. However, clinical pharmacokinetic studies are lacking.
MANAGEMENT: Coadministration of docetaxel with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided unless the benefit outweighs the potential risk of docetaxel underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with docetaxel is unknown.
- Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91
- "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
- Baker SD "Drug interactions with the taxanes." Pharmacotherapy 17(5 Pt 2) (1997): s126-32
- Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R "Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures." Clin Cancer Res 11(19 Pt 1) (2005): 6972-9
- McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110
Generic Name: docetaxel
Brand name: Taxotere, Docefrez
Synonyms: Docetaxel, DOCEtaxel
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Apalutamide-Docosavit
- Apalutamide-DocQLace Syrup
- Apalutamide-Doculax
- Apalutamide-Docuprene Tablets
- Apalutamide-Docusate
- Apalutamide-Docusate and senna
- Docetaxel Intravenous-APAP w/Codeine
- Docetaxel Intravenous-Apetex
- Docetaxel Intravenous-Apetigen
- Docetaxel Intravenous-Apetigen-Plus
- Docetaxel Intravenous-ApexiCon
- Docetaxel Intravenous-ApexiCon E